Literature DB >> 25676468

Binding of Complement Factor H (FH) Decreases Protective Anti-FH Binding Protein Antibody Responses of Infant Rhesus Macaques Immunized With a Meningococcal Serogroup B Vaccine.

Dan M Granoff1, Isabella Costa1, Monica Konar1, Serena Giuntini1, Koen K A Van Rompay2, Peter T Beernink1.   

Abstract

BACKGROUND: The meningococcal vaccine antigen, factor H (FH)-binding protein (FHbp), binds human complement FH. In human FH transgenic mice, binding decreased protective antibody responses.
METHODS: To investigate the effect of primate FH binding, we immunized rhesus macaques with a 4-component serogroup B vaccine (4CMenB). Serum FH in 6 animals bound strongly to FHbp (FHbp-FH(high)) and, in 6 animals, bound weakly to FHbp (FHbp-FH(low)).
RESULTS: There were no significant differences between the respective serum bactericidal responses of the 2 groups against meningococcal strains susceptible to antibody to the NadA or PorA vaccine antigens. In contrast, anti-FHbp bactericidal titers were 2-fold lower in FHbp-FH(high) macaques against a strain with an exact FHbp match to the vaccine (P = .08) and were ≥4-fold lower against 4 mutants with other FHbp sequence variants (P ≤ .005, compared with FHbp-FH(low) macaques). Unexpectedly, postimmunization sera from all 12 macaques enhanced FH binding to meningococci. In contrast, serum anti-FHbp antibodies elicited by 4CMenB in mice whose mouse FH did not bind to the vaccine antigen inhibited FH binding.
CONCLUSIONS: Binding of FH to FHbp decreases protective anti-FHbp antibody responses of macaques to 4CMenB. Even low levels of FH binding skew the antibody repertoire to FHbp epitopes outside of the FH-binding site, which enhance FH binding.
© The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  4CMenB; Bexsero; FH; factor H binding protein; nonhuman primate animal model

Mesh:

Substances:

Year:  2015        PMID: 25676468      PMCID: PMC4539902          DOI: 10.1093/infdis/jiv081

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  34 in total

1.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

2.  Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen.

Authors:  Jo Anne Welsch; Sanjay Ram; Oliver Koeberling; Dan M Granoff
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

3.  Group B meningococcal vaccine: recommendations for UK use.

Authors:  Andrew J Pollard; Andrew Riordan; Mary Ramsay
Journal:  Lancet       Date:  2014-03-21       Impact factor: 79.321

4.  Heterogeneity in rhesus macaque complement factor H binding to meningococcal factor H binding protein (FHbp) informs selection of primates to assess immunogenicity of FHbp-based vaccines.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Heather Stefek; Sanjay Ram; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2014-09-03

5.  A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.

Authors:  P C Richmond; M D Nissen; H S Marshall; S B Lambert; D Roberton; W C Gruber; T R Jones; A Arora
Journal:  Vaccine       Date:  2012-08-05       Impact factor: 3.641

6.  Importance of inhibition of binding of complement factor H for serum bactericidal antibody responses to meningococcal factor H-binding protein vaccines.

Authors:  Monica Konar; Dan M Granoff; Peter T Beernink
Journal:  J Infect Dis       Date:  2013-05-28       Impact factor: 5.226

7.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

8.  Meningococcal factor H-binding protein vaccines with decreased binding to human complement factor H have enhanced immunogenicity in human factor H transgenic mice.

Authors:  Raffaella Rossi; Dan M Granoff; Peter T Beernink
Journal:  Vaccine       Date:  2013-09-11       Impact factor: 3.641

9.  The effect of human factor H on immunogenicity of meningococcal native outer membrane vesicle vaccines with over-expressed factor H binding protein.

Authors:  Peter T Beernink; Jutamas Shaughnessy; Rolando Pajon; Emily M Braga; Sanjay Ram; Dan M Granoff
Journal:  PLoS Pathog       Date:  2012-05-10       Impact factor: 6.823

10.  Human factor H (FH) impairs protective meningococcal anti-FHbp antibody responses and the antibodies enhance FH binding.

Authors:  Isabella Costa; Rolando Pajon; Dan M Granoff
Journal:  mBio       Date:  2014-08-26       Impact factor: 7.867

View more
  19 in total

1.  A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes.

Authors:  Monica Konar; Rolando Pajon; Peter T Beernink
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

2.  Beyond the Crystal Structure: Insight into the Function and Vaccine Potential of TbpA Expressed by Neisseria gonorrhoeae.

Authors:  Devin R Cash; Nicholas Noinaj; Susan K Buchanan; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2015-09-08       Impact factor: 3.441

3.  Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020.

Authors:  Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil
Journal:  MMWR Recomm Rep       Date:  2020-09-25

4.  Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Authors:  Raffaella Rossi; Peter T Beernink; Serena Giuntini; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2015-09-30

5.  Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding.

Authors:  Dan M Granoff; Serena Giuntini; Flor A Gowans; Eduardo Lujan; Kelsey Sharkey; Peter T Beernink
Journal:  JCI Insight       Date:  2016-09-08

6.  Impaired Immunogenicity of Meningococcal Neisserial Surface Protein A in Human Complement Factor H Transgenic Mice.

Authors:  Eduardo Lujan; Rolando Pajon; Dan M Granoff
Journal:  Infect Immun       Date:  2015-11-23       Impact factor: 3.441

7.  Meningococcal Factor H Binding Protein Vaccine Antigens with Increased Thermal Stability and Decreased Binding of Human Factor H.

Authors:  Raffaella Rossi; Monica Konar; Peter T Beernink
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

8.  Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine.

Authors:  Serena Giuntini; Peter T Beernink; Dan M Granoff
Journal:  Vaccine       Date:  2015-11-10       Impact factor: 3.641

9.  A Meningococcal Native Outer Membrane Vesicle Vaccine With Attenuated Endotoxin and Overexpressed Factor H Binding Protein Elicits Gonococcal Bactericidal Antibodies.

Authors:  Peter T Beernink; Emma Ispasanie; Lisa A Lewis; Sanjay Ram; Gregory R Moe; Dan M Granoff
Journal:  J Infect Dis       Date:  2019-03-15       Impact factor: 5.226

10.  A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.

Authors:  Rolando Pajon; Eduardo Lujan; Dan M Granoff
Journal:  Vaccine       Date:  2015-12-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.